Overview of Spasticity Disorders

Clinical trials of medical marijuana on spasticity in multiple sclerosis sufferers have shown mixed results. In one trial, subjective perception of muscle spasticity decreased in the sufferers but observers saw no significant decrease and found that it further impaired coordination. Another study showed a marked decline in spasticity. However, this was not a blind study. Yet another involving a single patient showed nabilone -- synthetic THC -- decreased spasticity.

 These limited findings are consistent with what other medical marijuana research has found about the drug's effects on the body. There is significant evidence that medical marijuana can affect the central nervous system, which is where much spasticity originates. The endocannabinoid system is found virtually everywhere in the human body. Therefore, it is not a leap to suggest that medical marijuana can not only affect the root of the problem but also the spastic area in sufferers with nervous system disorders like multiple sclerosis.

Multiple sclerosis gets the most attention when it comes to spasticity. However, spinal cord injury is another leading cause of muscle spasticity. It is also another area of medical marijuana research. Like MS, spinal cord injury can cause pain that can be treated with medical marijuana. The spasticity found in spinal cord injury is also treatable with cannabis sativa and its derivatives. Also like MS, spinal cord injury sufferers will most often need long-term medical care. Therefore, safer alternatives to sedatives and traditional pain relievers are needed for these conditions. Medical marijuana is showing promise in that area as well.

Findings: Effects of Cannabis on Spasticity Disorders

A double-blind study of a paraplegic spinal cord injury sufferer showed that muscle spasticity decreased when the patient was given THC. Furthermore, it worked better than the codeine that the patient was receiving. This indicates that medical marijuana is not only a viable treatment but may also be more successful in some patients than existing treatments. Nonetheless, more research is certainly needed, as one patient cannot show how prevalent relief is among sufferers who are given medical marijuana.

As with other conditions treated with medical marijuana, the anecdotal evidence that it works is staggering. One study showed that nearly all of 112 survey respondents with multiple sclerosis had fewer incidences of muscle spasticity when taking marijuana. Another study of subjective sensations showed that nearly half experienced less spasticity when on medical marijuana. This is not overwhelming proof. However, it certainly suggests that medical marijuana can increase quality of life in many spasticity suffers. It also indicates that in-depth and solid research into the treatment of spasticity with medical marijuana is needed. Safe, effective and tested medications are always needed for chronic conditions such as spasticity. Until there is a way to cure the damage that leads to spasticity in most patients, it is the duty of the medical community to explore all avenues of relief for these sufferers.

 

References

  1. Blair, R.E., Deshpande, L.S., and  DeLorenzo, R.J. (2015, September). Cannabinoids: is there a potential treatment role in epilepsy? Expert Opinion on Pharmacology, 16(13), 1911-4. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4845642/.

  2. Boychuck, D.G., Goddard, G., Mauro, G., and Orellana, M.F. (2015 Winter). The effectiveness of cannabinoids in the management of chronic nonmalignant neuropathic pain: a systematic review. Journal of Oral & Facial Pain and Headache, 29(1), 7-14. Retrieved from https://goo.gl/R28LWD.

  3. Cerebral Palsy: Hope Through Research. (2015, July 2). National Institute of Neurological Disorders and Stroke. Retrieved from http://www.ninds.nih.gov/disorders/cerebral_palsy/detail_cerebral_palsy.htm#268993104.

  4. Devinsky, O., Cilio, M.R., Cross, H., Fernandez-Ruiz, J., French, J., Hill, C., Katz, R., Di Marzo, V., Jutras-Aswad, D., Notcutt, W.G., Martinez-Orgado, J., Robson, P.J., Rohrback, B.G., Thiele, E., Whalley, B., and Friedman, D. (2014, June). Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia, 55(6), 791-802. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4707667/.

  5. Facts About Cerebral Palsy. (2015, July 13). Centers for Disease Control and Prevention. Retrieved from http://www.cdc.gov/ncbddd/cp/facts.html.

  6. Hirsch, A.T., Kratz, A.L., Engel, J.M., and Jensen, M.P. (2011, March). Survey results of pain treatments in adults with cerebral palsy. American Journal of Physical Medicine & Rehabilitation, 90(3), 207-216. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3036542/.

  7. Lynch, M.E., and Campbell, F. (2011, November). Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. British Journal of Clinical Pharmacology, 72(5), 735-744. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3243008/.

  8. Maa, E. and Figi, P. (2014, June). The case for medical marijuana in epilepsy. Epilepsia, 55(6), 783-6. Retrieved from http://onlinelibrary.wiley.com/doi/10.1111/epi.12610/full.

  9. Mortati, K., Dworetzky, B., and Devinsky, O. (2007, Spring). Marijuana: an effective antiepileptic treatment in partial epilepsy? A case report and review of the literature. Reviews in Neurological Diseases, 4(2), 103-6. Retrieved from https://goo.gl/0nWcyV.

  10. Pertwee, R.G. (2002, August). Cannabinoids and multiple sclerosis. Pharmacology & Therapeutics, 95(2), 165-74. Retrieved from http://www.sciencedirect.com/science/article/pii/S0163725802002553.

  11. Rosenberg, E.C., Tsien, R.W., Whalley, B.J., and Devinsky, O. (2015, August 18). Cannabinoids and Epilepsy. Neurotherapeutics, Epub ahead of print. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4604191/.

  12. Shouman, B., Fontaine, R.H., Baud, O., Schwendimann, L., Keller, M., Spedding, M., Lelievre, V., and Gressens, P. (2006, June). Endocannabinoids potentially protect the newborn brain against AMPA-kainate receptor mediated excitotoxic damage. British Journal of Pharmacology, 149(4), 442-51. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1751782/.

  13. Syed, Y.Y., McKeage, K., and Scott, L.J. (2014, April). Delta-9-tetrahydrocannabinol-cannabidiol (Sativex): a review of its use in patients with moderate to severe spasticity due to multiple sclerosis. Drugs, 74(5), 563-78. Retrieved from http://link.springer.com/article/10.1007%2Fs40265-014-0197-5.

  14. Szaflarski, J.P., and Bebin, E.M. (2014, December). Cannabis, cannabidiol, and epilepsy–from receptors to clinical response. Epilepsy & Behavior, 41, 277-82. Retrieved from http://www.epilepsybehavior.com/article/S1525-5050(14)00413-2/fulltext.

  15. Ware, M.A., Doyle, C.R., Woods, R., Lynch, M.E., and Clark, A.J. (2003, March). Cannabis use for chronic non-cancer pain: results of a prospective survey. Pain, 102(1-2). Retrieved from http://journals.lww.com/pain/Abstract/2003/03000/Cannabis_use_for_chronic_non_cancer_pain__results.23.aspx.

© 2017 by qualifyingconditions. 

  • QualifyingConditions.com
  • Twitter Round
  • b-googleplus